Latest news with #OWS
Globe and Mail
16 hours ago
- Health
- Globe and Mail
Opioid Withdrawal Syndrome Market Insight, Epidemiology, and Market Forecast – 2034
Opioid Withdrawal Syndrome (OWS) is a major public health concern caused by the sudden reduction or cessation of opioids in dependent individuals. Symptoms like anxiety, cramps, and severe cravings make withdrawal a key barrier to recovery. With the ongoing opioid crisis, the demand for effective, accessible treatments continues to grow. DelveInsight's ' Opioid Withdrawal Syndrome Market Report ' offers a detailed analysis of the current and projected landscape for OWS treatment across the major markets, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report outlines the evolving epidemiology, highlighting the high prevalence of opioid dependence and withdrawal cases, particularly in countries severely impacted by opioid misuse. It also examines standard clinical practices and treatment gaps, providing a strategic overview of the healthcare burden and future market potential. Current treatment regimens for OWS typically involve a combination of opioid agonists such as buprenorphine and methadone, non-opioid medications like clonidine and lofexidine, and supportive symptom-based therapies. While effective to some extent, these approaches often face challenges related to tolerability, relapse risk, and access to care. The approval of non-opioid therapies like Lucemyra (lofexidine hydrochloride) has expanded options for managing withdrawal symptoms, but broader therapeutic innovation remains limited. Newer candidates in clinical development are targeting novel pathways to reduce withdrawal intensity and improve adherence during detoxification. With rising investments in addiction research, increasing awareness around opioid misuse, and supportive policy reforms in many countries, the OWS treatment market is set to evolve significantly by 2034. DelveInsight's report captures this transformation by evaluating market dynamics, key players, emerging therapies, and regulatory landscapes. It is an essential resource for pharmaceutical companies, healthcare providers, policymakers, and investors looking to understand and capitalize on the opportunities in this high-need therapeutic area. Some of the Key Facts of the Opioid Withdrawal Syndrome Market Report: • In 2022, the Opioid Withdrawal Syndrome market in the 7MM was valued at around USD 1.3 billion and is expected to grow steadily through 2034. • Approximately 8.2 million cases of opioid withdrawal syndrome were reported in the 7MM in 2022, with a projected decline over the forecast period. • Around 9.1 million individuals had long-term opioid use in the 7MM in 2022. • The US accounted for nearly 7.1 million opioid withdrawal cases in 2022, expected to decrease by 2034. • In March 2025, Hikma Pharmaceuticals announced that Health Canada approved KLOXXADO® (naloxone HCl) Nasal Spray 8 mg for the treatment of known or suspected opioid overdose, characterized by respiratory and/or central nervous system depression, in adult patients. • In February 2025, Indivior announced that the FDA approved label changes for SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The updates include a rapid initiation protocol reducing treatment time from one week to one hour and alternative injection sites to improve flexibility and patient adherence. • In October 2024, the FDA approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone IR 10 mg) for severe pain management. It is the first FDA-approved abuse-deterrent IR oxycodone designed to reduce intranasal and intravenous misuse. • Leading companies in the Opioid Withdrawal Syndrome market include atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Emerging acute Opioid Withdrawal Syndrome drugs include BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome remains a significant clinical challenge, with rising awareness and evolving treatment strategies driving demand for safer, more effective therapies to manage symptoms and reduce relapse risk. To know in detail about the Opioid Withdrawal Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Opioid Withdrawal Syndrome Market Forecast Opioid Withdrawal Syndrome Overview Opioid Withdrawal Syndrome (OWS) is a clinical condition that occurs when individuals who are physically dependent on opioids suddenly reduce or discontinue their use. This syndrome is a hallmark of opioid dependence and is driven by the neuroadaptive changes in the brain that result from prolonged exposure to opioids. When opioid use is stopped, the abrupt absence of the drug leads to a rebound of neurotransmitter activity, particularly within the noradrenergic and dopaminergic systems, triggering a range of distressing physical and psychological symptoms. Symptoms of opioid withdrawal typically begin within hours of the last dose and can vary in intensity depending on the type of opioid used, duration of use, and individual factors such as tolerance and overall health. Common early symptoms include anxiety, agitation, muscle aches, sweating, and insomnia. These may progress to more severe manifestations such as abdominal cramps, vomiting, diarrhea, dilated pupils, rapid heartbeat, and intense cravings. While not usually life-threatening, the severity of symptoms can lead to significant discomfort and increase the risk of relapse. Get a free sample of the Opioid Withdrawal Syndrome market report with key insights and emerging therapies here: Opioid Withdrawal Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Opioid Withdrawal Syndrome Epidemiology Segmentation: The Opioid Withdrawal Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Number of Opioid Misuse Cases • Number of Cases with long term Opioid usage • Total Opioid Withdrawal symptoms Cases Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Epidemiology Forecast Opioid Withdrawal Syndrome Drugs Uptake and Pipeline Development Activities The Opioid Withdrawal Syndrome drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Opioid Withdrawal Syndrome market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Opioid Withdrawal Syndrome pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Opioid Withdrawal Syndrome Market Outlook The Opioid Withdrawal Syndrome (OWS) market is expected to witness steady growth through 2034, driven by the increasing prevalence of opioid use disorder (OUD), rising awareness about withdrawal management, and expanding access to treatment services. As the opioid crisis continues to pose a significant public health burden across the globe, particularly in the United States and parts of Europe, the demand for effective withdrawal therapies is accelerating. The availability of both opioid-based and non-opioid pharmacological options, including buprenorphine and clonidine, is enhancing treatment outcomes and reducing relapse rates, contributing to market expansion. Furthermore, advancements in withdrawal management protocols, growing governmental and private sector investments in addiction care, and the development of more targeted and patient-friendly therapeutics are fueling innovation in the OWS treatment landscape. The emergence of new formulations, such as long-acting buprenorphine and novel non-opioid agents, is expected to diversify the treatment arsenal and improve patient adherence. With continued efforts toward destigmatization and the integration of mental health support, the OWS market is poised for sustained progress over the forecast period. Opioid Withdrawal Syndrome Market Strengths • Increased global awareness about the opioid crisis, coupled with supportive government policies, funding, and public health initiatives, has significantly strengthened the market. Programs promoting medication-assisted treatment (MAT) and opioid withdrawal management have expanded access to care, thereby boosting demand for therapeutic options. • The development of innovative pharmacological treatments, such as non-opioid medications (e.g., lofexidine) and extended-release formulations of buprenorphine, has improved treatment adherence and outcomes. These advancements enhance patient experience and create opportunities for differentiated products in the market. Opioid Withdrawal Syndrome Market Weaknesses • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. Scope of the Opioid Withdrawal Syndrome Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Opioid Withdrawal Syndrome Companies: atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Key Opioid Withdrawal Syndrome Therapies: BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome Therapeutic Assessment: Opioid Withdrawal Syndrome, currently marketed, and Opioid Withdrawal Syndrome emerging therapies • Opioid Withdrawal Syndrome Market Dynamics: Opioid Withdrawal Syndrome market drivers and Opioid Withdrawal Syndrome market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Opioid Withdrawal Syndrome Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal Syndrome Market Access and Reimbursement To learn more about the key players and advancements in the Opioid Withdrawal Syndrome treatment landscape, visit the Opioid Withdrawal Syndrome Market Analysis Report Table of Contents 1. Opioid Withdrawal Syndrome Market Report Introduction 2. Executive Summary for Opioid Withdrawal Syndrome 3. SWOT analysis of Opioid Withdrawal Syndrome 4. Opioid Withdrawal Syndrome Patient Share (%) Overview at a Glance 5. Opioid Withdrawal Syndrome Market Overview at a Glance 6. Opioid Withdrawal Syndrome Disease Background and Overview 7. Opioid Withdrawal Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Opioid Withdrawal Syndrome 9. Opioid Withdrawal Syndrome Current Treatment and Medical Practices 10. Opioid Withdrawal Syndrome Unmet Needs 11. Opioid Withdrawal Syndrome Emerging Therapies 12. Opioid Withdrawal Syndrome Market Outlook 13. Country-Wise Opioid Withdrawal Syndrome Market Analysis (2020–2034) 14. Opioid Withdrawal Syndrome Market Access and Reimbursement of Therapies 15. Opioid Withdrawal Syndrome Market Drivers 16. Opioid Withdrawal Syndrome Market Barriers 17. Opioid Withdrawal Syndrome Appendix 18. Opioid Withdrawal Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
India.com
30-05-2025
- Business
- India.com
Govt Imposes Wheat Stock Limits On Traders To Keep Prices In Check
New Delhi: The Centre has imposed stock limits on wheat applicable to traders/wholesalers, retailers, big chain retailers and processors in order to prevent hoarding and speculation that drives up inflation. "In order to manage the overall food security and to prevent hoarding and unscrupulous speculation, the Government of India has imposed stock limits on wheat applicable to wholesalers, retailers, big chain retailers, and processors in all states and Union Territories,' the Ministry of Consumer Affairs, Food & Public Distribution said on Thursday. The Wheat Stock limit are as under: (i) Traders/Wholesaler: 3000 MT; (ii) Retailer: 10 MT for each Retail outlet. (iii) Big Chain Retailer: upto 10 MT for each retail outlet subject to maximum quantity of (10 multiplied by total no. of outlets) MT. This will be the maximum stock that can be held at all their retail outlets and depots put together. (iv) Processors: 70% of Monthly Installed Capacity (MIC) multiplied by remaining months of FY 2025-26. All wheat stocking entities are required to declare/ update the stock position on every Friday on wheat stock portal ( which will be migrated in due course of time to Any entity which is found to have not registered on the portal or violates the stock limits will be subject to suitable punitive action under Section 6 & 7 of Essential Commodities Act,1955. In case the stocks held by above entities are higher than the above prescribed limit, they shall have to bring the same to the prescribed stock limits within 15 days of issue of the notification. Officials of Central and State Governments will be closely monitoring enforcement of these stock limits to ensure that no artificial scarcity of wheat is created in the country. Central Government has procured 298.17 LMT wheat (upto 27.05.2025) through State Agencies/FCI which is sufficient to meet requirement of PDS, OWS and other market intervention schemes. The Department of Food and Public Distribution is maintaining a close watch over the stock position of wheat to control prices and ensure easy availability in the country.
India Gazette
29-05-2025
- Business
- India Gazette
Centre imposes wheat stock limits on Traders to manage overall food security
New Delhi [India], May 29 (ANI): In order to manage the overall food security and to prevent hoarding and unscrupulous speculation, the government has imposed stock limits on wheat applicable to traders, wholesalers, retailers, big chain retailers and processors in all states and Union Territories. The removal of licensing requirements, stock limits and movement restrictions on Specified Foodstuffs (Amendment) Order, 2025 is issued on May 27 and is applicable until March 31, 2026, for all states and Union Territories, Ministry of Consumer Affairs, Food & Public Distribution said in an official statement on Thursday. The Wheat Stock limit are as under: Traders/Wholesaler: 3000 MT; Retailer: 10 MT for each Retail outlet; Big Chain Retailer: upto 10 MT for each retail outlet subject to maximum quantity of (10 multiplied by total no. of outlets) MT. This will be the maximum stock that can be held at all their retail outlets and depots put together; Processors: 70 per cent of Monthly Installed Capacity (MIC) multiplied by remaining months of FY 2025-26. All wheat stocking entities are required to declare the stock position on every Friday on wheat stock portal which will be migrated in due course of time. Any entity which is found to have not registered on the portal or violates the stock limits will be subject to suitable punitive action under Section 6 & 7 of Essential Commodities Act,1955, as per the ministry. In case the stocks held by above entities are higher than the above prescribed limit, they shall have to bring the same to the prescribed stock limits within 15 days of issue of the notification. Officials of Central and State Governments will be closely monitoring enforcement of these stock limits to ensure that no artificial scarcity of wheat is created in the country. The Central government has procured 298.17 LMT wheat (upto 27.05.2025) through state agencies, FCI which is sufficient to meet requirements of PDS, OWS and other market intervention schemes. The Department of Food and Public Distribution is maintaining a close watch over the stock position of wheat to control prices and ensure easy availability in the country. (ANI)
India Today
07-05-2025
- Health
- India Today
Indian-American doctor and anti-vaxxer picked to lead FDA's vaccines division
Indian-origin hematologist-oncologist Vinay Prasad was named the Director of the Center for Biologics Evaluation and Research (CBER), the vaccines division of the US Food and Drug Administration (FDA). Prasad had previously criticised the FDA and was a fierce critic of the Covid-19 vaccine and mask mandates, news agency Reuters reported. Following the appointment of Vinay Prasad, shares of vaccine-makers like Moderna and Pfizer dipped by 3% to 20%. FDA Commissioner Marty Makary made the announcement in an email to staff on Tuesday. CBER, a division under the FDA, oversees vaccines and biologic medicines. In the email, Makary wrote that Prasad has a "long and distinguished history in medicine" and highlighted his extensive oncology research. Prasad is set to succeed Peter Marks, who led the division for 13 years and shaped the Operation Warp Speed (OWS) effort to develop Covid-19 vaccines. The OWS, is a public-private partnership initiated by the US government during the pandemic to accelerate the development, manufacturing, and distribution of vaccines, therapeutics, and diagnostics. Prasad joins the FDA from the University of California, San Francisco, where he served as an epidemiology professor. He holds a medical degree from the University of Chicago and has prior experience at the National Cancer Institute and the National Institutes of Health. PETER MARKS SLAMS FDA OVER PRASAD'S APPOINTMENT Marks resigned from his post in March this year, citing US Health and Human Services Secretary Robert F Kennedy Jr.'s stance on vaccine safety. "It has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies," CNN quoted Marks as saying. During the Covid-19 pandemic, Prasad emerged as a vocal critic of the government's response and vaccine policies. Prasad vociferously condemned the Warp Speed effort and Marks' leadership on his blog and on the social media platform X, where he was often praised by now-FDA Commissioner Dr. Marty Makary for criticizing school shutdowns, mask policies, and the COVID-19 booster shot, CNN reported. Prasad's appointment as head of the Center for Biologics Evaluation and Research coincides with the FDA's announcement of new requirements for future vaccines, mandating placebo studies. SHARES OF VACCINE-MAKERS PFIZER, GENE, OTHERS HIT Shares of vaccine maker Moderna (NASDAQ: MRNA) dropped approximately 10% following the announcement of Prasad's appointment as CBER Director, while Pfizer saw a 3% decline, according to Reuters. Smaller gene therapy companies like Sarepta Therapeutics and Taysha Gene Therapies experienced steeper losses, plunging around 20%.
Yahoo
25-04-2025
- Climate
- Yahoo
When are tornado sirens triggered in Shawnee County?
SHAWNEE COUNTY (KSNT) – Shawnee County Emergency Management (SNCO EM) gave an update on its Outdoor Warning System (OWS) policy this week. SNCO EM reported on April 24 that when a tornado watch is issued, it moves into an increased 'Situational Awareness' posture. SNCO EM teams start by emailing partners and making notifications through social media. More team members are activated as risks increase. Once a warning is issued through the National Weather Service (NWS) or a trusted agent, the sirens in the warned area, using a specific location, will be activated. Once activated, the system will run for two to three minutes and then break. The system will be reactivated and the process is repeated until the warning expires or is cancelled. 61st year for biggest car part swap meet in Kansas The Shawnee County Consolidated Emergency Communication Center can work as a backup to activate the OWS. The SNCO EM says the ability to activate the OWS for a specific area may not be possible, resulting in an all-county activation. 'The previous policy of an all-county activation is not desired however, the objective of this policy is to warn people in the event of a life-threatening situation in order to preserve life and prevent human suffering.' SNCO EM policy guide excerpt A tornado watch means the conditions in our atmosphere are favorable for severe weather and you still have time to prepare. But as soon as a tornado warning is issued, it's time to take cover inside of a sturdy structure because severe weather is immediate or actively occurring. In the case of a tornado, that means that either rotation has been indicated on radar or a trained spotter has seen a tornado. Just after 4:45 p.m. on Wednesday, April 23, the NWS issued tornado warnings for multiple northeast Kansas counties. Tornado warnings were issued in Jefferson, Shawnee and Jackson counties. Are there public tornado shelters in NE Kansas? 'This thing popped up so fast and it just said tornado warning Shawnee County, we weren't clear where it was so we sounded all county sirens, then once we figured out where it was we shut those all down and just sounded those sirens in that warned area up north,' said Shawnee County Emergency Director Dusty Nichols. The next policy review date will be on March 1, 2026. For more local news, click here. Keep up with the latest breaking news in northeast Kansas by downloading our mobile app and by signing up for our news email alerts. Sign up for our Storm Track Weather app by clicking here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
